The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Long-term follow-up of the CARTITUDE-4 trial: improved OS & PFS with cilta-cel in R/R myeloma
In this video, Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses an updated 34-month follow-up analysis of the CARTITUDE-4 trial (NCT04181827). Dr Popat highlights that ciltacabtagene autoleucel (cilta-cel) improved both progression-free survival and overall survival (PFS; OS) compared to standard of care (SoC) in patients with multiple myeloma who had received one to three prior lines of therapy, with deeper responses and higher rates of measurable residual disease (MRD) negativity observed over time. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
